Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery
PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.
'We are thrilled to advance our clinical trials by integrating Veeva Clinical Platform into our digital toolkit,' said SCRI chief information and digital officer Yazhene Krishnaraj. 'This strategic collaboration empowers our clinical teams to deliver groundbreaking therapies to patients with enhanced precision and speed.'
Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites.
'We're excited to work closely with SCRI to drive innovation in oncology research,' said Jim Reilly, president of Veeva Development Cloud. 'In a first-of-a-kind partnership, Veeva Clinical Platform will serve as SCRI's clinical trial foundation for its CRO and SMO. By standardizing operations on one platform, we can support SCRI in delivering faster and more cost-effective trials.'
About Veeva Clinical Platform
Veeva Clinical Platform is a complete and connected platform across clinical operations and data applications. This end-to-end platform includes CTMS, EDC, clinical workbench (CDB), RTSM, eCOA, eTMF, Site Connect, Study Training, and more. Connected products streamline clinical trials from study start-up to close and automate a connected data flow. To learn more about Veeva Clinical Platform, visit veeva.com/VeevaClinicalPlatform.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's strategic collaboration with SCRI and the expected results or benefits from such collaboration. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
View original content to download multimedia: https://www.prnewswire.com/news-releases/veeva-and-sarah-cannon-research-institute-form-strategic-collaboration-to-advance-oncology-clinical-trials-302472592.html
SOURCE Veeva Systems
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
NGL Energy Partners (NGL): Among the Energy Stocks that Gained This Week
The share price of NGL Energy Partners LP (NYSE:NGL) surged by 12.73% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A pipeline stretching through a desert valley, a symbol of the companies transportation infrastructure. NGL Energy Partners LP (NYSE:NGL) is a diversified midstream MLP that provides multiple services to producers and end-users, including transportation, storage, blending, and marketing of crude oil, NGLs, refined products/renewables, and water solutions. NGL Energy Partners LP (NYSE:NGL) received a boost after posting strong results for its Q4 2025 last week, highlighting strong performance in its Water Solutions segment and successful asset sales that have led to significant debt reduction. The company reported an income from continuing operations of $65 million for FY 2025, compared to a loss from continuing operations of $157.7 million the previous year. NGL's adjusted EBITDA for FY 2025 came in at $622.9 million, surpassing its previous guidance of $620 million. NGL Energy Partners LP (NYSE:NGL) recently executed the sale of 18 natural gas liquids terminals and monetized several other non-core assets, helping the company optimize its asset portfolio and strengthen its balance sheet. While we acknowledge the potential of NGL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Centuri Holdings (CTRI) Surged This Week. Here is Why.
The share price of Centuri Holdings, Inc. (NYSE:CTRI) surged by 9.74% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A close-up of an electrical power line with a bright blue sky in the background, highlighting the company's selection of electricity and natural gas services. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) continues to surge after the company announced $350 million in new customer awards in late May, reflecting strong demand for the company's infrastructure solutions across North America. The awards span the United States and include work supporting electric and gas infrastructure modernization, water relocation, utility distribution, and renewables. This comes after Centuri Holdings had already announced nearly $490 million in multi-year customer awards earlier this year. The share price of Centuri Holdings, Inc. (NYSE:CTRI) has gained almost 23% over the last month. While we acknowledge the potential of CTRI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Why Sitio Royalties Corp. (STR) Gained This Week
The share price of Sitio Royalties Corp. (NYSE:STR) surged by 13.29% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A close-up of an oil derrick against a colorful sunset sky, a symbol of the company's success. Sitio Royalties Corp. (NYSE:STR) received a boost this week after it was announced that the company is set to be acquired by Viper Energy, a subsidiary of Diamondback Energy. The all-equity deal is valued at around $4.1 billion, including Sitio's net debt of approximately $1.1 billion as of March 31, 2025. The transaction is subject to customary regulatory approvals and is expected to close in the third quarter of this year. Chris Conoscenti, CEO of Sitio Royalties Corp. (NYSE:STR), stated: 'We are excited to announce the combination of two leading minerals companies with a shared strategic vision of integrating the highest quality assets to create a truly differentiated investment opportunity for shareholders. While we acknowledge the potential of STR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None.
